Mirum Pharmaceuticals, Inc. (MIRM) Stock

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies tailored for rare and orphan diseases that significantly impact patients' lives. At the forefront of its portfolio is LIVMARLI, the company's lead product candidate. This investigational oral drug shows promise in treating progressive familial intrahepatic cholestasis disease, Alagille syndrome, and biliary atresia disease, addressing critical unmet medical needs in these conditions.

In addition to LIVMARLI, Mirum Pharmaceuticals is advancing Volixibat, another important therapeutic candidate designed for the treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. These developments highlight the company's commitment to expanding treatment options for patients affected by liver-related disorders.

Founded in 2018 and headquartered in Foster City, California, Mirum Pharmaceuticals leverages its specialized expertise and strategic focus to accelerate the development of novel therapies. The company's efforts are supported by a dedicated team and collaborative partnerships aimed at advancing breakthrough treatments for rare diseases. Mirum Pharmaceuticals continues to drive innovation in the biopharmaceutical industry, striving to make a meaningful impact on patient care and disease management globally.

Mirum Pharmaceuticals, Inc. operates with a mission to address the significant medical needs of patients with rare and orphan diseases through innovative research, development, and commercialization strategies. With a robust pipeline and a focus on advancing therapies that offer new hope for patients, the company remains committed to achieving transformative outcomes in the field of biopharmaceuticals.